Association of Use of ACEI, ARB With Testing Positive for COVID-19

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 5, 2020

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2020.1855?guestAccessKey=ab9ada9a-e796-4ae8-891c-4bb318235c24&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050520

 

What The Study Did: This observational study assessed the association between the use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with the likelihood of testing positive for coronavirus disease 2019 (COVID-19).

Authors: Ankur Kalra, M.D., of the Cleveland Clinic in Akron, Ohio, is the corresponding author.

 

(doi:10.1001/jamacardio.2020.1855)

Editor’s Note: The article contains conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.